Deals Buzz: Sanofi SA set to buy US drug maker Bioverativ for more than $11.5 billion
In other news, Carlyle Group is leading the race to invest as much as $500 million for a 15% stake in Mankind Pharmaceuticals23-01-2018
Deals Buzz: Sanofi SA set to buy US drug maker Bioverativ for more than $11.5 billion
In other news, Carlyle Group is leading the race to invest as much as $500 million for a 15% stake in Mankind PharmaceuticalsStatement Of Investor Complaints For The Quarter Ended December, 2017
Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 please find enclosed statement of investor complaints/grievances for the quarter ended 31st December 2017.Shareholding for the Period Ended December 31, 2017
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click hereResignation of Director
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. A K Ravi Nedungadi vide his letter dated 15th January 2018 informed the Company that after serving on the Board for over 17 years, he would like to focus on various other matters that require his immediate attention and will not have sufficient time to do justice to his responsibilities as an Independent...Updates
As required under regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors has authorised the Managing Director and Chief Financial Officer to determine materiality of an event or information in line with the said Regulations. The Board has also authorised the Company Secretary to disclose such information to the Stock Exchanges....How biotech CEO John Hood turned failed Sanofi drug into multibillion deal
In April 2016, John Hood put down a quarter million dollars to try and buy back a drug he'd helped invent after it had failed in the hands of drugmaker SanofiSanofi India Limited
Sanofi India has elevated N Rajaram as Managing Director, effective January 1, and he will be succeeding Shailesh Ayyangar, who will take up a regional role within Sanofi Asia. Rajaram joined Sanofi...Press Release / Media Release
We enclose herewith a copy of press release on the above subject, contents of which are self-explanatory for your information and records.Letters: Unwitting savior
Only a total ban on Sanofi and summary dismissal of all those concerned with the matter at WHO might meet the demands of social justice